Olanzapine + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Nov 1, 2002 → Apr 1, 2005
NCT ID
NCT00051298About Olanzapine + Placebo
Olanzapine + Placebo is a phase 3 stage product being developed by Eli Lilly for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00051298. Target conditions include Schizophrenia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00520507 | Approved | Completed |
| NCT00510146 | Phase 3 | Completed |
| NCT00091650 | Phase 3 | Completed |
| NCT00051298 | Phase 3 | Completed |
| NCT00050206 | Approved | Completed |
| NCT00592930 | Approved | Completed |
Competing Products
20 competing products in Schizophrenia